$AMIX

Autonomix Medical (AMIX) appointed Sandra Kalter, former Medtronic VP, to its board. Kalter brings 40+ years of medical tech, FDA regulatory, and transaction experience. She will advise on tech development, therapeutic applications, and industry partnerships. Autonomix is developing a nerve-sensing platform for cardiology, hypertension, and chronic pain management.

Autonomix Medical, Inc. (AMIX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervat

Autonomix Medical (AMIX) will hold its annual meeting on October 29, 2026, to vote on a reverse stock split (ratio 1-for-2 to 1-for-25), expand its equity incentive plan, and elect directors. The company seeks approval for the board to implement the split within a year, which would reduce share count but maintain ownership percentages. AMIX had 1,828,505 shares outstanding as of September 8, 2026.

Autonomix Medical, Inc. (AMIX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules THE WOODLANDS, TX, August 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedic

Autonomix Medical (NASDAQ: AMIX) received a new U.S. patent (No. 12,714,780) for systems integrating real-time feedback, sensing, and imaging with controlled therapeutic delivery, including neural ablation for cancer pain. The patent covers systems regulating treatment based on physiological feedback and has applications in neuromodulation and targeted ablation. The company believes this strengthens its IP position and supports its technology platform's advancement.

Several biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.

Autonomix Medical (AMIX) announced a $4.9M warrant inducement agreement with an investor. The deal involves exercising July 2026 warrants for 857,462 shares at $5.75 per share. The company will also issue new warrants for 535,913 shares each, exercisable at $6.25 per share. The transaction is expected to close on August 26, 2026, subject to customary conditions.

Autonomix Medical (AMIX) received a U.S. patent for its precision nerve sensing and cancer pain therapy technology. The patent covers systems to sense, map, and target nerves associated with tumors and cancer-related pain. The company's shares surged 116.73% to $5.97 in extended trading following the announcement and positive preclinical results for resistant hypertension treatment.

Autonomix Medical (NASDAQ:AMIX) said it completed a Good Laboratory Practice pre-clinical study for its Autonomix platform, generating safety and performance data in porcine models across multiple anatomical targets, according to the company. The results are expected to support planned FDA submissions as part of its regulatory package.

Autonomix Medical Inc. (AMIX) shares fell about 33.85% as dilution and warrant-related supply concerns weighed on sentiment. The company filed a prospectus for resale of up to 857,462 shares and previously completed a warrant inducement deal raising about $2.6M. AMIX also reported about $7.0M cash and no long-term debt, but ongoing operating cash outflows.